Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sviluppo di biomarcatori dell'assunzione dietetica

Background:

- Researchers who study health and nutrition are interested in developing more accurate methods of determining what people eat from day to day and how it affects their general health. In particular, better methods are needed to determine if people are accurately remembering what they ate. One possible method involves the use of biomarkers, or indicators in urine, blood, saliva, fat, and hair, which are related to the intake of a particular food in a consistent way. One set of biomarkers in blood samples and hair may be used to determine the relative amount of meat, fish, and soda (corn/sugar cane) in a person s diet. However, more research is needed to study the effectiveness of using these biomarkers to accurately track dietary intake.

Objectives:

- To validate the use of biomarkers as representative of specific dietary intake patterns (meat/fish/soda).

Eligibility:

- Healthy, nondiabetic men between 18 and 65 years of age.

Design:

  • This study involves an initial screening visit and a 12-13 week inpatient dietary study period.
  • Participants will be screened with a medical history and physical examination, as well as blood and urine samples and a glucose tolerance test to exclude individuals who have diabetes.
  • After 3 days of a standard weight-maintaining diet, participants will have a glucose tolerance test and a body fat scan; provide hair, blood, and fat tissue samples; and complete questionnaires and performance tests.
  • Participants will spend one day in a metabolic chamber to measure their energy expenditure and general metabolism.
  • Participants will then be randomized into one of eight carefully designed diets for 12 weeks. The diets will differ in the amount of meat, fish, and soda, including one diet where none of the three biomarker-related foods will be permitted. Blood samples will be collected throughout the study diet period.
  • At the end of the 12-week study diet period, participants will provide additional hair, blood, and fat tissue samples, and will have a second metabolism assessment in the metabolic chamber.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Studies of health and nutrition use a variety of tools to determine what people eat from day to day. Unfortunately, most of the methods used are not accurate for a variety of reasons and do not provide solid information on which to base health recommendations or public policy. In general, when people are asked to keep track of what they eat or recall what they have eaten in the past, they make mistakes in estimating both amounts and specifics of what was eaten. New tools that can help determine if people are accurately remembering what they ate are desperately needed.

Biomarkers are things that can be measured (in urine, blood, hair, etc.) which are related to the intake of a particular food in a consistent way and may therefore be more accurate than a food record. One set of biomarkers that may be used are naturally occurring (present in all foods) stable isotopes of carbon and nitrogen to determine the relative amount of meat, fish, and soda (corn/sugar cane) in a person s diet. These isotopes can be measured in blood samples and hair.

The aim of this study is to validate the use of stable isotope biomarkers as representative of specific dietary intake patterns (meat/fish/soda). This study will be an inpatient study in which highly specific diets will be fed to volunteers for ~12 weeks and stable isotopes will be measured in blood and hair. The ultimate goal is to develop biomarkers to be used to validate food intake patterns in outpatient clinical and epidemiological studies.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

59

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85014
        • NIDDK, Phoenix

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Maschio

Descrizione

  • INCLUSION CRITERIA:
  • Body mass index less than or equal to 35 kg/m(2) to minimize the impact of body size on isotope measurements.
  • Males 18-65 years old will be recruited for this study. Minors under the age of 18 will be excluded because the time requirements of the study are such that they would interfere with school schedules.

Healthy, as determined by medical history, physical examination, and laboratory tests.

EXCLUSION CRITERIA:

  • Current smoking
  • Female sex
  • Baldness or hair less than 2 cm in length
  • Medically- or self-imposed dietary restrictions that would limit a participant s ability/willingness to consume the diet to which they are randomized.
  • Type 2 diabetes (according to the World Health Organization diagnostic criteria)
  • Endocrine disorders (Cushing s Disease, pituitary disorders, and hypo- and hyperthyroidism)
  • Chronic pulmonary disorders, including chronic obstructive pulmonary disease, that would limit ability to follow the protocol (investigator judgment) and obstructive sleep apnea syndrome; only subjects with mild or exercise-induced asthma on no medications or on beta-adrenergic agonists only (such as albuterol) will be allowed to enter the study (provided use of these agents is not required for one week before study entry).
  • Cardiovascular diseases (coronary heart disease, heart failure, arrhythmias, and peripheral artery disease)
  • Hypertension (blood pressure measurement higher than 140/90 mm Hg on two or more occasions or use of anti-hypertensive medications)
  • Diagnosed gastrointestinal diseases, including inflammatory bowel diseases (e.g., Crohn s disease and ulcerative colitis), malabsorption syndromes (e.g., celiac disease), gastric ulcer (active); only subjects with gastro-esophageal reflux will be allowed to enter the study
  • Presence of a pacemaker or other implantable devices
  • Liver disease (cirrhosis, active hepatitis B or C, and AST or ALT greater than or equal to 1.5 x normal)
  • Renal disease (serum creatinine concentrations greater than or equal to 1.5 mg/dl and/or greater than 100mg/dl of protein based on urine dipstick)
  • Central nervous system disease (cerebrovascular accidents, dementia, and neurodegenerative disorders)
  • Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis
  • Alcohol (more than 3 drinks per day) and/or drug abuse (such as amphetamines, cocaine, heroin, or marijuana)
  • Current or past history of: bipolar disorder, schizophrenia or presence of psychotic symptoms, bulimia nervosa or anorexia nervosa, or current major depressive disorder
  • Weight change of plus or minus 5% in the last 3 months

Conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the investigators. Additionally, potential subjects might be excluded if they demonstrate a style of interpersonal relationships that would inhibit successful completion of the study.

Non-English speaking subjects as a population will be excluded from participation in this protocol. One of the secondary hypotheses of the protocol relates to a battery of psychological questionnaires and performances tests which are administered to the volunteers at the beginning and end of the study. There are currently no validated, translated forms of these questionnaires and tests available; therefore we will restrict enrollment to English speaking subjects only.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: 1. Meat, no fish or soda

weight maintaining diet with meat but no fish or soda for 12 weeks

weight maintaining diet with meat but no fish or soda

Sperimentale: 2. Meat and soda, no fish

weight maintaining diet with meat and soda but no fish for 12 weeks

weight maintaining diet with meat and soda but no fish

Sperimentale: 4. Meat and fish and soda

weight maintaining diet with meat, fish, and soda for 12 weeks

weight maintaining diet with meat, fish and soda

Sperimentale: 5. Fish, no meat or soda

weight maintaining diet with meat, fish, and soda for 12 weeks

weight maintaining diet with fish but no meat or soda

Sperimentale: 6. Fish and soda, no meat

weight maintaining diet with fish and soda but no meat for 12 weeks

weight maintaining diet with fish and soda but no meat

Sperimentale: 7. No meat, fish, or soda

no fish, and no soda (vegetarian) for 12 weeks

weight maintaining diet with no meat, no fish, and no soda (vegetarian)

Sperimentale: 8. Soda, no meart or fish

weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks

weight maintaining diet with soda but no meat or fish (vegetarian + soda)

Sperimentale: Meat and fish, no soda

weight maintaining diet with meat and fish but no soda for 12 weeks

weight maintaining diet with meat and fish but no soda

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in NIR
Lasso di tempo: Weeks 0, 2, 4, 6, 8, 10, 12

Change in nitrogen stable isotope rations (N15/N14)

Weeks 0, 2, 4, 6, 8, 10, 12
Change in CR
Lasso di tempo: Weeks 0, 2, 4, 6, 8, 10, 12

Change in carbon stable isotope ratios (13C/12C)

Weeks 0, 2, 4, 6, 8, 10, 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
OGTT
Lasso di tempo: Settimane 0 e 12
Settimane 0 e 12
Performance tests
Lasso di tempo: Weeks 0 and 12

Iowa Card Setting Test, Stroop Color Word Test, Wisconsin Card Sorting Test, Go/No Go Task

Weeks 0 and 12
Lipid panel
Lasso di tempo: Weeks 0 and 12

LDL, HDL, Triglycerides and Total Cholesterol

Weeks 0 and 12
Respiratory quotient (RQ)
Lasso di tempo: Weeks 0 and 12

Ratio of the volume of carbon dioxide (CO2) produced to the volume of oxygen (O2) used, or VCO2/VO2

Weeks 0 and 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Susanne M Votruba, Ph.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

24 ottobre 2010

Completamento primario (Effettivo)

31 marzo 2020

Completamento dello studio (Effettivo)

31 marzo 2020

Date di iscrizione allo studio

Primo inviato

6 novembre 2010

Primo inviato che soddisfa i criteri di controllo qualità

6 novembre 2010

Primo Inserito (Stimato)

9 novembre 2010

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 ottobre 2026

Ultimo verificato

16 marzo 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 999911018
  • 11-DK-N018

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .